Supplier-branded blend of GHK-Cu, BPC-157, TB-500, and KPV
Commonly listed as an 80mg vial (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 + 10mg KPV), though exact ratios vary by supplier.
This page is for educational and informational purposes only. PeptideSuppliers.org does not sell peptides, provide medical advice, or recommend human use.
KLOW is not a single peptide. It is a supplier-coined name for a pre-mixed blend that combines four separately studied compounds in one vial: GHK-Cu, BPC-157, TB-500, and KPV.
The most common published ratio is 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500, and 10mg KPV for an 80mg total blend, though suppliers can vary the exact milligram split, so the label on any given listing should always be checked directly.
Skin, collagen, and wound-healing research (from GHK-Cu), tissue-repair research (from BPC-157 and TB-500), and inflammatory-response research (from KPV).
Preclinical for all four ingredients individually; the combined blend itself has no dedicated trial record.
Use the linked literature searches for current papers and trial records on each component peptide.
Because KLOW is a named combination rather than a single molecule, the relevant research sits with its four ingredients individually: GHK-Cu's role in collagen and extracellular matrix biology, BPC-157 and TB-500's roles in tissue-repair and angiogenesis models, and KPV's role in inflammatory-response research.
Each ingredient has its own preclinical literature, but the specific combined formula sold as "KLOW" has not itself been studied as a unit in published research.
GHK-Cu is a copper-binding tripeptide studied for roles in collagen synthesis, extracellular matrix remodeling, and antioxidant activity, which is why it anchors the skin-related positioning in this blend.
BPC-157 and TB-500 (thymosin beta-4) are both studied in tissue-repair and wound-healing models, including tendon, ligament, and gastrointestinal research for BPC-157, and angiogenesis and actin-binding research for TB-500.
KPV is a tripeptide derived from the C-terminus of alpha-MSH, studied for anti-inflammatory activity, which is the reason it is added to this blend alongside the repair-focused peptides.
Because the blend combines four independently studied peptides rather than testing the mixture itself, a reader should evaluate the documentation for each ingredient separately rather than treating "KLOW" as a single research-backed entity.
A trustworthy KLOW listing should spell out the exact milligram amount of all four ingredients, provide a batch-specific COA for the finished blend, and avoid implying the combination itself has been clinically tested.
Use these pages to compare naming, documentation access, and overall page clarity.
This listing is useful for checking naming, documentation access, and overall page clarity.
10% off with code IRONMANQuick answers to the main questions that come up on this page.
KLOW is a supplier-branded name for a peptide blend that combines GHK-Cu, BPC-157, TB-500, and KPV in one vial, most commonly formulated as 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500, and 10mg KPV (an 80mg total blend). It is not a single studied compound; it is a mixture of four separately studied peptides.
Each ingredient carries its own research base: GHK-Cu is linked to skin, collagen, and wound-healing research; BPC-157 and TB-500 are linked to tissue-repair research; KPV is linked to inflammatory-response research. There is little to no published literature testing the specific combined formula itself.
KLOW is essentially GLOW (GHK-Cu, BPC-157, TB-500) with KPV added as a fourth ingredient, which is why the two names are often listed side by side by the same suppliers.
Not as a combined formula. The published research covers each of the four ingredients individually rather than the specific pre-mixed blend sold under this name.
Look for a supplier page that lists the exact milligram breakdown of all four ingredients, provides a batch-specific COA covering the finished blend, and avoids treating the combination as if it had its own dedicated clinical evidence.